[ad_1]
Survivors of frequent lymphoid neoplasms (LNs) have elevated dangers for therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML), though dangers have been decrease in more moderen years, in line with a examine printed within the July difficulty of eClinicalMedicine.
Lindsay M. Morton, Ph.D., from the Nationwide Most cancers Institute in Bethesda, Maryland, and colleagues recognized 1,496 tMDS/AML instances amongst 186,503 adults who have been handled with preliminary chemotherapy/immunotherapy for first main LN and survived one 12 months or longer.
The researchers discovered that the best dangers for tMDS/AML occurred after precursor leukemia/lymphoma (standardized incidence ratio [SIR]39; extra absolute dangers [EAR]30 per 10,000 person-years), Burkitt leukemia/lymphoma (SIR, 20; EAR, 24), peripheral T-cell lymphoma (SIR, 12; EAR, 23), power lymphocytic leukemia/small lymphocytic lymphoma (SIR, 9.0; EAR, 27), and mantle cell lymphoma (SIR, 8.5; EAR, 25).
In any case different LN subtypes besides bushy cell leukemia and mycosis fungoides/Sézary syndrome, elevated dangers have been additionally noticed (SIRs, 4.2 to six.9; EARs, 4.9 to fifteen). For sufferers handled extra not too long ago, tMDS/AML dangers have been considerably increased after chronic lymphocytic leukemia/small lymphocytic lymphoma (SIR2000-20054.8; SIR2012-201710), considerably decrease after Hodgkin (SIR2000-200515; SIR2012-20176.3) and marginal zone (SIR2000-20057.5; SIR2012-20172.3) lymphomas, and nonsignificantly decrease after mantle cell lymphoma, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, and plasma cell neoplasms. Developments for EAR and cumulative incidence have been typically just like these of SIR. Median survival was 8.0 months after tMDS/AML.
“Inhabitants-based information present that sufferers handled with preliminary chemo/immunotherapy for many lymphoid neoplasms might face elevated tMDS/AML dangers, however that tMDS/AML dangers have developed in step with adjustments in therapy practices for sure subtypes,” the authors write.
Extra data:
Lindsay M. Morton et al, Developments in danger for therapy-related myelodysplastic syndrome/acute myeloid leukemia after preliminary chemo/immunotherapy for frequent and uncommon lymphoid neoplasms, 2000–2018, eClinicalMedicine (2023). DOI: 10.1016/j.eclinm.2023.102060
Copyright © 2023 HealthDay. All rights reserved.
Quotation:
Examine finds elevated MDS/leukemia dangers for survivors of frequent lymphoid neoplasms (2023, August 17)
retrieved 18 August 2023
from https://medicalxpress.com/information/2023-08-mdsleukemia-survivors-common-lymphoid-neoplasms.html
This doc is topic to copyright. Aside from any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.
[ad_2]
Source link
Discussion about this post